Ligand Pharms Glucagon
Ligand Pharmaceuticals Incorporated, a biopharmaceutical company, develops and licenses biopharmaceutical assets worldwide. It offers Pradefovir, Posaconazole, Voriconazole, CAPVAXIVE, NOXAFIL, MenFive, and ZELSUVMI for infectious disease; EVOMELA and KYPROLIS for multiple myeloma; FILSPARI, a dual endothelin and angiotensin II receptor antagonist for immunoglobulin A nephropathy; Ohtuvayre for r… Read more
Market Cap & Net Worth: Ligand Pharms Glucagon (LGNXZ)
Ligand Pharms Glucagon (PINK:LGNXZ) has a market capitalization of $28.39 ($28.39) as of March 18, 2026. Listed on the PINK stock exchange, this USA-based company holds position #42082 globally and #13647 in its home market, demonstrating a 0.00% increase in market value over the past year.
Market capitalization, also known as net worth in stock markets, is calculated by multiplying Ligand Pharms Glucagon's stock price $0.00 by its total outstanding shares 9462 (9.46K).
Ligand Pharms Glucagon Market Cap History: 2015 to 2025
Ligand Pharms Glucagon's market capitalization history from 2015 to 2025. Data shows change from $302.78 to $28.39 (-27.17% CAGR).
Ligand Pharms Glucagon Market Cap to Earnings & Revenue Ratios Timeline
This chart shows how Ligand Pharms Glucagon's valuation ratios have evolved. The Price to Sales (P/S) ratio compares market cap to revenue, while the Price to Earnings (P/E) ratio compares market cap to net income. Lower values may indicate a more undervalued company relative to its financial performance.
Latest Price to Sales (P/S) Ratio
0.00x
Ligand Pharms Glucagon's market cap is 0.00 times its annual revenue
Latest Price to Earnings (P/E) Ratio
0.00x
Ligand Pharms Glucagon's market cap is 0.00 times its annual earnings
What These Ratios Tell Investors:
- Price to Sales (P/S) Ratio: Shows how much investors are paying for each dollar of the company's sales. Lower P/S ratios may indicate undervaluation.
- Price to Earnings (P/E) Ratio: Shows how much investors are paying for each dollar of the company's earnings. This is one of the most common valuation metrics.
- Trends in these ratios over time can indicate changing investor sentiment about the company's future growth prospects.
- Industry comparison provides context for whether the company is valued higher or lower than peers.
| Year | Market Cap (USD) | Revenue (USD) | Net Income (USD) | P/S Ratio | P/E Ratio |
|---|---|---|---|---|---|
| 2015 | $302.78 | $71.91 Million | -$184.27 Million | 0.00x | N/A |
| 2016 | $167.48 | $108.97 Million | $18.29 Million | 0.00x | 0.00x |
| 2017 | $889.43 | $141.10 Million | $101.91 Million | 0.00x | 0.00x |
| 2018 | $473.10 | $251.45 Million | $143.32 Million | 0.00x | 0.00x |
| 2019 | $331.17 | $120.28 Million | $629.30 Million | 0.00x | 0.00x |
| 2020 | $37.85 | $186.42 Million | -$2.98 Million | 0.00x | N/A |
| 2021 | $56.77 | $241.54 Million | $57.14 Million | 0.00x | 0.00x |
| 2022 | $47.31 | $196.25 Million | -$33.36 Million | 0.00x | N/A |
| 2023 | $12.30 | $131.31 Million | $52.15 Million | 0.00x | 0.00x |
| 2024 | $37.85 | $167.13 Million | $9.07 Million | 0.00x | 0.00x |
Competitor Companies of LGNXZ by Market Capitalization
Companies near Ligand Pharms Glucagon in the global market cap rankings as of March 18, 2026.
Key companies related to Ligand Pharms Glucagon by market ranking:
- Branded Legacy Inc (PINK:BLEG): Ranked #42073 globally with a market cap of $56.91K USD.
- Multitude AG (XETRA:MULT): Ranked #42074 globally with a market cap of $56.87K USD ( €55.41K EUR).
- Florence One Capital Inc. (V:FONC-P): Ranked #42083 globally with a market cap of $56.57K USD ( CA$81.25K CAD).
- Edel AG (HM:EDL): Ranked #42084 globally with a market cap of $56.53K USD ( €55.07K EUR).
| Rank | Company | Symbol | Market Cap | Price |
|---|---|---|---|---|
| #42073 | Branded Legacy Inc | PINK:BLEG | $56.91K | $0.00 |
| #42074 | Multitude AG | XETRA:MULT | $56.87K | €6.10 |
| #42083 | Florence One Capital Inc. | V:FONC-P | $56.57K | CA$0.04 |
| #42084 | Edel AG | HM:EDL | $56.53K | €5.65 |
Ligand Pharms Glucagon Historical Marketcap From 2015 to 2025
Between 2015 and today, Ligand Pharms Glucagon's market cap moved from $302.78 to $ 28.39, with a yearly change of -27.17%.
| Year | Market Cap | Change (%) |
|---|---|---|
| 2025 | $28.39 | -25.00% |
| 2024 | $37.85 | +207.69% |
| 2023 | $12.30 | -74.00% |
| 2022 | $47.31 | -16.67% |
| 2021 | $56.77 | +50.00% |
| 2020 | $37.85 | -88.57% |
| 2019 | $331.17 | -30.00% |
| 2018 | $473.10 | -46.81% |
| 2017 | $889.43 | +431.07% |
| 2016 | $167.48 | -44.69% |
| 2015 | $302.78 | -- |
End of Day Market Cap According to Different Sources
On Mar 18th, 2026 the market cap of Ligand Pharms Glucagon was reported to be:
| Source | Market Cap |
|---|---|
| Yahoo Finance | $28.39 USD |
| MoneyControl | $28.39 USD |
| MarketWatch | $28.39 USD |
| marketcap.company | $28.39 USD |
| Reuters | $28.39 USD |
Market cap values may vary slightly between sources due to differences in calculation methods, timing, and data refresh rates.